search
Back to results

Activ-L™ Artificial Disc Treatment of Degenerative Disc Disease in the Treatment of Degenerative Disc Disease

Primary Purpose

Degenerative Disc Disease

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Activ-L Artificial Disc
ProDisc-L Total Disc Replacement or Charité Artificial Disc
Sponsored by
Aesculap Implant Systems
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Degenerative Disc Disease focused on measuring Degenerative, Disc

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Age 18 - 60, skeletally mature Symptomatic DDD with objective evidence of lumbar DDD, with any of the following characteristics by MRI scan: instability as defined by ≥ 3mm translation or ≥ 5° angulation. osteophyte formation of facet joints or vertebral endplates. decreased disc height of >2mm as compared to the adjacent level. scarring/thickening of the ligamentum flavum, annulus fibrosis, or facet joint capsule. herniated nucleus pulposus. facet joint degeneration/changes. vacuum phenomenon. Single level symptomatic disease at L4/L5 or L5/S1. six months of unsuccessful conservative treatment ODI score ≥ 40/100. Surgical candidate for an anterior approach to the lumbar spine. Back pain at the operative level only, with or without leg pain. Back pain VAS score greater than the higher of the two VAS leg pain scores. VAS back pain score ≥ 40/100 mm. Willing to return for follow-up visits and sign an Informed Consent and HIPAA Authorization. Exclusion Criteria: Previous surgery at any lumbar level, except IDET (Intradiscal Electrothermal Annuloplasty), percutaneous nucleoplasty, or microdiscectomy. Chronic radiculopathy, i.e., subject complaint of unremitting pain with a predominance of leg pain symptoms greater than back pain symptoms extending over a period of at least 1 year. endplate dimensions smaller than 34.5 mm in medial-lateral and/or 27 mm in the anterior-posterior direction Evidence of significant, symptomatic disc degeneration at another lumbar level. Preoperative remaining disc height < 3mm Myelopathy. Previous compression or burst fracture at the affected level. Sequestered herniated nucleus pulposus with migration. Mid-sagittal stenosis of <8mm (by MRI). Degenerative or lytic spondylolisthesis > 3mm. Spondylolysis. Isthmic spondylolisthesis. Lumbar scoliosis (> 11 degrees of sagittal plane deformity). Spinal tumor. Active systemic infection or infection at the site of surgery. Facet ankylosis or severe facet degeneration. Continuing steroid use or prior use for more than 2 months. History of allergies to any of the device components. Pregnancy or planning to become pregnant within the next 2 years. Morbid obesity (BMI >35). Investigational drug or device use within 30 days. Osteoporosis or osteopenia Metabolic bone disease. Leg pain with migrated sequestrum fragment. History of rheumatoid arthritis, lupus, or other autoimmune disorder. Ankylosing spondylitis. History of HIV/AIDS or hepatitis that precludes surgery. History of deep vein thrombosis, symptoms of arterial insufficiency, or thromboembolytic disease. Current or recent history of illicit drug or alcohol abuse, or dependence as defined as the continued use of alcohol despite the development of social, legal, or health problems. Life expectancy <5 years. Chemotherapy within past 5 years or any cancer other than non-melanoma skin cancer treated with curative intent within the past 5 years. Prior nephrectomy. Abdominal adhesions, endometriosis, inflammatory bowel disease, Crohn's disease, diverticulitis, ulcerative colitis or other abdominal pathology that would preclude abdominal surgical approach. Insulin-dependent diabetes. Any degenerative muscular or neurological condition that would interfere with evaluation of outcomes, including but not limited to Parkinson's disease, ALS (amyotrophic lateral sclerosis), or multiple sclerosis. History of Pelvic Inflammatory Disease. Peritonitis. Currently in active spinal litigation as a result of medical negligence. Prisoner. Psychiatric or cognitive impairment that would interfere with the subject's ability to comply with the study requirements, e.g., Alzheimer's disease.

Sites / Locations

  • Scripps Memorial Hospital La Jolla
  • Hoag Memorial Hospital Presbyterian
  • Rancho Specialty Hospital
  • University of California San Francisco
  • St. John's Hospital and Health Center
  • University of Colorado Health Sciences Center
  • Yale University School of Medicine/New Haven Hospital
  • Aventura Hospital and Medical Center
  • University Community Hospital
  • Rush University Medical Center
  • Neurosciences Education and Research Foundation
  • HealthEast St. John's Hospital
  • Hospital for Special Surgery
  • Carolinas Healthcare
  • University Hospitals of Cleveland
  • Hamot Medical Center
  • University of Utah

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Investigational

Control

Arm Description

Implantation of the Activ-L Artificial Disc at one level of the lumbar spine, either L4/L5 or L5/S1.

Implantation of either the ProDisc-L Total Disc Replacement or Charité Artificial Disc at one level of the lumbar spine, either L4/L5 or L5/S1.

Outcomes

Primary Outcome Measures

Overall Success at 24 Months Relative to Baseline
Measured by absence of treatment failure; absence or serious device related AE; maintenance or improvement of ROM at index level; maintenance or improvement of neurological status; improvement in ODI score.
Device Success
Percent of subjects demonstrating no Subsequent Surgical Interventions (SSI's) at the index level (L4-L5 or L5-S1) at 24 months.
Absence of Serious Device Related Adverse Events
Percent of subjects demonstrating no device related SAE's at 24 months as per the Clinical Events Committee (CEC)
Range of Motion (ROM) Success
Percent of subjects demonstrating maintenance or improvement in ROM at 24 months compared to baseline
Neurological Success
Percent of patients demonstrating maintenance or improvement in combined motor and sensory evaluations at 24 months compared to baseline
ODI Success
Percent of subjects demonstrating an improvement of greater than or equal to 15 points at 24 months compared to baseline

Secondary Outcome Measures

VAS Success for Back and Leg Pain at Rest
Number of patients demonstrating improvement in back and leg pain at 24 months compared to baseline
ODI Success Using Two Measures of Success
Number of subjects demonstrating improvement in two measures of ODI success at 24 months compared to baseline
Improvement in SF-36 Scores
Number of subjects demonstrating a greater than or equal to 15% improvement in mental (MCS) and physical (PCS) component summary scores at 24 months compared to baseline

Full Information

First Posted
December 26, 2007
Last Updated
November 12, 2018
Sponsor
Aesculap Implant Systems
search

1. Study Identification

Unique Protocol Identification Number
NCT00589797
Brief Title
Activ-L™ Artificial Disc Treatment of Degenerative Disc Disease in the Treatment of Degenerative Disc Disease
Official Title
Clinical Study to Evaluate the Safety and Effectiveness of the Aesculap Activ-L™ Artificial Disc in the Treatment of Degenerative Disc Disease
Study Type
Interventional

2. Study Status

Record Verification Date
November 2018
Overall Recruitment Status
Completed
Study Start Date
January 2007 (undefined)
Primary Completion Date
December 2012 (Actual)
Study Completion Date
January 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Aesculap Implant Systems

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to learn whether an investigational device called the Activ-L Artificial Disc is safe and effective in the treatment of degenerative disc disease of the lower (lumbar) spine.
Detailed Description
The objective of this clinical study is to evaluate the safety and effectiveness of the Activ-L Artificial Disc for treatment of single-level degenerative disc disease of the lumbar spine in patients who have been unresponsive to at least six months of prior conservative care. The hypothesis of the study is that the Activ-L Disc is non-inferior to the control (the Charité® Artificial Disc [DePuy Spine] or ProDisc-L® Total Disc Replacement [Synthes Spine]) with respect to the rate of individual subject success at 24 months. Individual subject success is a composite of effectiveness and safety.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Degenerative Disc Disease
Keywords
Degenerative, Disc

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
376 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Investigational
Arm Type
Experimental
Arm Description
Implantation of the Activ-L Artificial Disc at one level of the lumbar spine, either L4/L5 or L5/S1.
Arm Title
Control
Arm Type
Active Comparator
Arm Description
Implantation of either the ProDisc-L Total Disc Replacement or Charité Artificial Disc at one level of the lumbar spine, either L4/L5 or L5/S1.
Intervention Type
Device
Intervention Name(s)
Activ-L Artificial Disc
Intervention Description
Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
Intervention Type
Device
Intervention Name(s)
ProDisc-L Total Disc Replacement or Charité Artificial Disc
Intervention Description
Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
Primary Outcome Measure Information:
Title
Overall Success at 24 Months Relative to Baseline
Description
Measured by absence of treatment failure; absence or serious device related AE; maintenance or improvement of ROM at index level; maintenance or improvement of neurological status; improvement in ODI score.
Time Frame
24 months
Title
Device Success
Description
Percent of subjects demonstrating no Subsequent Surgical Interventions (SSI's) at the index level (L4-L5 or L5-S1) at 24 months.
Time Frame
24 months
Title
Absence of Serious Device Related Adverse Events
Description
Percent of subjects demonstrating no device related SAE's at 24 months as per the Clinical Events Committee (CEC)
Time Frame
24 months
Title
Range of Motion (ROM) Success
Description
Percent of subjects demonstrating maintenance or improvement in ROM at 24 months compared to baseline
Time Frame
24 months
Title
Neurological Success
Description
Percent of patients demonstrating maintenance or improvement in combined motor and sensory evaluations at 24 months compared to baseline
Time Frame
24 months
Title
ODI Success
Description
Percent of subjects demonstrating an improvement of greater than or equal to 15 points at 24 months compared to baseline
Time Frame
24 months
Secondary Outcome Measure Information:
Title
VAS Success for Back and Leg Pain at Rest
Description
Number of patients demonstrating improvement in back and leg pain at 24 months compared to baseline
Time Frame
24 months
Title
ODI Success Using Two Measures of Success
Description
Number of subjects demonstrating improvement in two measures of ODI success at 24 months compared to baseline
Time Frame
24 months
Title
Improvement in SF-36 Scores
Description
Number of subjects demonstrating a greater than or equal to 15% improvement in mental (MCS) and physical (PCS) component summary scores at 24 months compared to baseline
Time Frame
24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age 18 - 60, skeletally mature Symptomatic DDD with objective evidence of lumbar DDD, with any of the following characteristics by MRI scan: instability as defined by ≥ 3mm translation or ≥ 5° angulation. osteophyte formation of facet joints or vertebral endplates. decreased disc height of >2mm as compared to the adjacent level. scarring/thickening of the ligamentum flavum, annulus fibrosis, or facet joint capsule. herniated nucleus pulposus. facet joint degeneration/changes. vacuum phenomenon. Single level symptomatic disease at L4/L5 or L5/S1. six months of unsuccessful conservative treatment ODI score ≥ 40/100. Surgical candidate for an anterior approach to the lumbar spine. Back pain at the operative level only, with or without leg pain. Back pain VAS score greater than the higher of the two VAS leg pain scores. VAS back pain score ≥ 40/100 mm. Willing to return for follow-up visits and sign an Informed Consent and HIPAA Authorization. Exclusion Criteria: Previous surgery at any lumbar level, except IDET (Intradiscal Electrothermal Annuloplasty), percutaneous nucleoplasty, or microdiscectomy. Chronic radiculopathy, i.e., subject complaint of unremitting pain with a predominance of leg pain symptoms greater than back pain symptoms extending over a period of at least 1 year. endplate dimensions smaller than 34.5 mm in medial-lateral and/or 27 mm in the anterior-posterior direction Evidence of significant, symptomatic disc degeneration at another lumbar level. Preoperative remaining disc height < 3mm Myelopathy. Previous compression or burst fracture at the affected level. Sequestered herniated nucleus pulposus with migration. Mid-sagittal stenosis of <8mm (by MRI). Degenerative or lytic spondylolisthesis > 3mm. Spondylolysis. Isthmic spondylolisthesis. Lumbar scoliosis (> 11 degrees of sagittal plane deformity). Spinal tumor. Active systemic infection or infection at the site of surgery. Facet ankylosis or severe facet degeneration. Continuing steroid use or prior use for more than 2 months. History of allergies to any of the device components. Pregnancy or planning to become pregnant within the next 2 years. Morbid obesity (BMI >35). Investigational drug or device use within 30 days. Osteoporosis or osteopenia Metabolic bone disease. Leg pain with migrated sequestrum fragment. History of rheumatoid arthritis, lupus, or other autoimmune disorder. Ankylosing spondylitis. History of HIV/AIDS or hepatitis that precludes surgery. History of deep vein thrombosis, symptoms of arterial insufficiency, or thromboembolytic disease. Current or recent history of illicit drug or alcohol abuse, or dependence as defined as the continued use of alcohol despite the development of social, legal, or health problems. Life expectancy <5 years. Chemotherapy within past 5 years or any cancer other than non-melanoma skin cancer treated with curative intent within the past 5 years. Prior nephrectomy. Abdominal adhesions, endometriosis, inflammatory bowel disease, Crohn's disease, diverticulitis, ulcerative colitis or other abdominal pathology that would preclude abdominal surgical approach. Insulin-dependent diabetes. Any degenerative muscular or neurological condition that would interfere with evaluation of outcomes, including but not limited to Parkinson's disease, ALS (amyotrophic lateral sclerosis), or multiple sclerosis. History of Pelvic Inflammatory Disease. Peritonitis. Currently in active spinal litigation as a result of medical negligence. Prisoner. Psychiatric or cognitive impairment that would interfere with the subject's ability to comply with the study requirements, e.g., Alzheimer's disease.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rolando Garcia, M.D.
Organizational Affiliation
Orthopedic Care Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
James J Yue, M.D.
Organizational Affiliation
Yale University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dom Coric, M.D.
Organizational Affiliation
Carolina Neurosurgery and Spine Associates
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Steven Dennis, M.D.
Organizational Affiliation
Hoag Memorial Hospital Presbyterian
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Federico P. Girardi, M.D.
Organizational Affiliation
Hospital for Special Surgery, New York
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mick Perez-Cruet, M.D.
Organizational Affiliation
Michigan Head and Spine Institute
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Harel Deutsch, M.D.
Organizational Affiliation
Rush University Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Glenn Buttermann, M.D.
Organizational Affiliation
Midwest Spine Institute
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dzung Dinh, M.D.
Organizational Affiliation
Neuroscience Education and Research Foundation
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Vikas Patel, M.D.
Organizational Affiliation
University of Colorado, Denver
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Christopher Ames, M.D.
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
John Regan, M.D.
Organizational Affiliation
St. John's Hospital and Health Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Andrew Dailey, M.D.
Organizational Affiliation
University of Utah Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Darren Bergey, M.D.
Organizational Affiliation
Rancho Specialty Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Brian Dalton, M.D.
Organizational Affiliation
Hamot Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Scott Leary, M.D.
Organizational Affiliation
Scripps Memorial Hospital La Jolla
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
David Hart, M.D.
Organizational Affiliation
University Hospitals Cleveland
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Antonio Castellvi, M.D.
Organizational Affiliation
Foundatin for Orthopaedic Research and Education
Official's Role
Principal Investigator
Facility Information:
Facility Name
Scripps Memorial Hospital La Jolla
City
La Jolla
State/Province
California
ZIP/Postal Code
92037
Country
United States
Facility Name
Hoag Memorial Hospital Presbyterian
City
Newport Beach
State/Province
California
ZIP/Postal Code
92658
Country
United States
Facility Name
Rancho Specialty Hospital
City
Rancho Cucamonga
State/Province
California
ZIP/Postal Code
91730
Country
United States
Facility Name
University of California San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Facility Name
St. John's Hospital and Health Center
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Facility Name
University of Colorado Health Sciences Center
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Facility Name
Yale University School of Medicine/New Haven Hospital
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06520
Country
United States
Facility Name
Aventura Hospital and Medical Center
City
Aventura
State/Province
Florida
ZIP/Postal Code
33180
Country
United States
Facility Name
University Community Hospital
City
Tampa
State/Province
Florida
ZIP/Postal Code
33613
Country
United States
Facility Name
Rush University Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60612
Country
United States
Facility Name
Neurosciences Education and Research Foundation
City
Peoria
State/Province
Illinois
ZIP/Postal Code
61605
Country
United States
Facility Name
HealthEast St. John's Hospital
City
Maplewood
State/Province
Minnesota
ZIP/Postal Code
55109
Country
United States
Facility Name
Hospital for Special Surgery
City
New York
State/Province
New York
ZIP/Postal Code
10021
Country
United States
Facility Name
Carolinas Healthcare
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28203
Country
United States
Facility Name
University Hospitals of Cleveland
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Facility Name
Hamot Medical Center
City
Erie
State/Province
Pennsylvania
ZIP/Postal Code
16507
Country
United States
Facility Name
University of Utah
City
Salt Lake City
State/Province
Utah
ZIP/Postal Code
84112
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
20380708
Citation
Yue JJ, Mo FF. Clinical study to evaluate the safety and effectiveness of the Aesculap Activ-L artificial disc in the treatment of degenerative disc disease. BMC Surg. 2010 Apr 9;10:14. doi: 10.1186/1471-2482-10-14.
Results Reference
derived

Learn more about this trial

Activ-L™ Artificial Disc Treatment of Degenerative Disc Disease in the Treatment of Degenerative Disc Disease

We'll reach out to this number within 24 hrs